Abstract
Use of large language models for generative tasks in critical domains like medicine is fraught with challenges like hallucination. In the domain of medicine, hallucination may take a unique shape where the LLM-generated language is not inaccurate but the suggested treatment or medication has now been discontinued in a specific context. Reinforcement learning based solutions for building reliable LLM-based frameworks are limited by the fact that the reinforcement is typically focused on only identifying the mistake; correcting the mistake is left up to the primary LLM. We propose an innovative solution where a two-phase question answering framework composed of two LLMs is designed such that one LLM learns to generate answers while the other learns to correct any mistakes in the answer generated by the first model. We experimented with the particular domain of prostate cancer and LLMs designed for various domains and showed that domain-specific LLMs outperform generic or wide-domain LLMs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted by transforming the text of prostate cancer treatment guidelines of American Cancer Society into question-answer pairs. The treatment guidelines are available at https://www.cancer.org/cancer/types/prostate-cancer/treating.html Curated question-answer pairs can be made available upon reasonable request.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
